Your institution may have access to this item. Find your institution then sign in to continue.
Title
Generic and Biosimilar Drugs Generate $408 Billion in Savings for America's Patients and Healthcare System in 2022: But the sustainability of generic competition is at risk.
Abstract
The article focuses on the significant savings generated by generic and biosimilar medicines in the U.S. healthcare system, totaling 408 billion U.S. dollars in 2022, with more than 90 percent of prescriptions filled being generic or biosimilar drugs. It is discussed that these drugs accounted for a minimal percentage of total prescription drug spending, emphasizing their cost-effectiveness and essential role in reducing healthcare expenses.